Provider: View Press Release
Type: Link
Title: New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients | GSK
Description: GSK today announced new 48-week data from the MOMENTUM phase III trial...
Provider: View Press Release
Type: Link
Title: PERLA phase II trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in first-line metastatic non-squamous non-small cell lung cancer | GSK
Description: PERLA is the largest global head-to-head trial of PD-1 inhibitors in this patient population
Provider: View Press Release
Type: Link
Title: Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer | GSK
Description: Regulatory submissions based on the trial results are planned for the first half of 2023.
Provider: View Press Release
Type: Link
Title: European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis | GSK
Description: Application includes data from key phase III trials, including the pivotal MOMENTUM trial.
Provider: View Press Release
Type: Link
Title: New global survey reveals opportunities to address organ damage risk with people living with lupus earlier in the course of their disease | GSK
Description: Survey examined healthcare professional approaches to preventing organ damage
Provider: View Press Release
Type: Link
Title: GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation | GSK
Description: GSK has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf)